Huntington's Disease Research
Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.
Huntington's Disease Research Products Targets
- Adenosine A2A Receptor (11)
- Caspase (9)
- Ubiquitin-activating Enzyme E1 (3)
- Ubiquitin E2 Conjugating Enzyme (3)
- Ubiquitin E3 Ligase (10)
- Deubiquitinating Enzyme (12)
- Hsp90 (10)
- Hsp70 (4)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- Vesicular Monoamine Transporter (4)
- Sir 2-like Family Deacetylase (9)
- Post-Translational Modification (11)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- ERK (6)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Calpain (7)
- Trk Receptor (13)
- Autophagy (44)
- Antioxidant (19)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- Cathepsin (9)
- Mitochondrial Permeability Transition Pore (3)
- Proteasome (5)
- Histone Deacetylase (19)
- Histone Acetyltransferase (4)
Products for Huntington's Disease Research - Page 29
- Cat.No. Product Name Information/Activity
-
BCC7619
Ro 61-8048
Ro 61-8048 is a potent and selective inhibitors of kynurenine hydroxylase with IC50 of 37 nM.
-
BCC7655
Ro 8-4304 hydrochloride
1312991-77-7
-
BCC6992
SDZ 220-040
174575-40-7
-
BCC1939
SDZ 220-581
SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7.
-
BCC6730
Synthalin sulfate
182285-12-7
-
BCC6122
TCN 201
852918-02-6
-
BCC6123
TCN 213
556803-08-8
-
BCC6111
TCN 237 dihydrochloride
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
-
BCC7482
TCS 46b
302799-86-6
-
BCC6984
CCMQ
132623-44-0
